Genelux Corporation
NASDAQ:GNLXBiotechnology
+$0.08 today
- Market cap
- $107.66M
- Beta
- 0.55
- P/E (TTM)
- -3.0
- EPS (TTM)
- -$0.98
Volume 0.80M
Average 0.19M
GNLX Operating Cash Flow
Cash generated by the company's core business operations during the period.
Genelux CorporationNASDAQ: GNLX
Operating Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Operating cash flow grows, but more slowly than its trailing trend
Q1 FY2026 operating cash flow of $6.06M (cash outflow) rose 11.5% year over year, behind the +16.1% change in trailing-twelve-month operating cash flow. Sequentially, it fell 2.3% from the prior quarter. Over 3 fiscal years it compounded at +92.0% a year.
Context
- Operating cash flow amounted to 315850.0% of revenue in FY2025, up 50500.0 pp from a year earlier.
- Operating cash flow grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth recovers from +11.5% toward the trailing-twelve-month pace of +16.1%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Operating Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (25.27M) USD
- Year-over-year change
- -19.0%
| Period | Period end | Operating Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (25.27M) | -19.0% |
| FY2024 | 2024-12-31 | (21.23M) | -4.7% |
| FY2023 | 2023-12-31 | (20.28M) | -467.8% |
| FY2022 | 2022-12-31 | (3.57M) | +45.8% |
| FY2021 | 2021-12-31 | (6.59M) | — |
Operating Cash Flow vs competitors
How GNLX compares with its peers on the latest reported figures
- Peers report in different currencies, so operating cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +16.1% is the 3rd highest of 9, against a peer median of -21.2%.
- Operating cash flow amounts to 323650.0% of revenue for GNLX, versus a peer median of 5390.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $133.8M USD | -23.6% | -4.0% | 431600.0% | |
LXEOLexeo Therapeutics, Inc. Common Stock | LTM Mar 2026 | $97.99M USD | +11.4% | +21.8% | — |
| LTM Dec 2025 | CHF 69.2M CHF | -205.1% | -3.5% | 1936.8% | |
| LTM Mar 2026 | $65.57M USD | — | +3.0% | 7115.1% | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | $57.17M USD | +46.0% | +40.1% | — |
| LTM Mar 2026 | $47.73M USD | +75.5% | +6.8% | — | |
| LTM Mar 2026 | $37.91M USD | -230.1% | -22.9% | 55.7% | |
| LTM Mar 2026 | $26.95M USD | -18.7% | -14.1% | 5390.8% | |
| LTM Dec 2025 | $26.68M USD | — | +3.8% | — | |
| LTM Mar 2026 | $25.99M USD | -43.1% | -16.2% | — | |
GNLXGenelux Corporation | LTM Mar 2026 | $25.89M USD | +16.1% | +92.0% | 323650.0% |
| Peer median (excluding GNLX) | — | -21.2% | -0.3% | 5390.8% | |
Competitors are the stored peer set for GNLX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (16.38M) | (5.21M) | (28.3M) | (29.87M) | (32.15M) |
| Depreciation & Amortization | 895K | 968K | 1.02M | 903K | 244K |
| Deferred Income Tax | 348K | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.27M | 2.42M | 5.2M | 6.07M | 5.87M |
| Change in Working Capital | 4.08M | (1.69M) | (3.28M) | 751K | (1.05M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 754K | 2.31M | (2.36M) | 2.16M | (1.21M) |
| Other Working Capital | 3.33M | (4M) | (923K) | (1.41M) | 167K |
| Other Non-Cash Items | 196K | (56K) | 5.08M | 917K | 1.81M |
| Operating Cash Flow | (6.59M) | (3.57M) | (20.28M) | (21.23M) | (25.27M) |
| Capital Expenditures | 0 | (49K) | (1.03M) | (381K) | (1.1M) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | (13.7M) | (29M) | (18.26M) |
| Sales of Investments | 0 | 0 | 0 | 21.25M | 31.5M |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | 0 | (49K) | (14.72M) | (8.13M) | 12.14M |
| Debt Repayment | (558K) | 970K | 215K | 0 | 0 |
| Common Stock Issued | 143K | 120K | 39.65M | 27.82M | 9.9M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 145K | (1.45M) | 4.16M | 688K | 0 |
| Financing Cash Flow | (270K) | (478K) | 44.02M | 28.51M | 9.9M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | (6.86M) | (4.1M) | 9.02M | (853K) | (3.23M) |
| Free Cash Flow | (6.59M) | (3.62M) | (21.3M) | (21.61M) | (26.37M) |
Genelux Corporation
NASDAQ:GNLX
Intrinsic Alpha fair value
Locked
Current Price
$2.24
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.